Sharescart Research Club logo

Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹8820 Cr.
Stock P/E
45.3
P/B
5.7
Current Price
₹1345.2
Book Value
₹ 235.5
Face Value
10
52W High
₹1618.2
52W Low
₹ 1152.1
Dividend Yield
0.07%

Jupiter Life Line Overview

Business

Jupiter Life Line Hospitals Ltd. is a multi-specialty tertiary and quaternary healthcare provider operating in the Western India region. The company primarily offers comprehensive medical services across various disciplines, including but not limited to cardiac sciences, neurosciences, oncology, orthopedics, gastroenterology, and pediatrics. Its core business model involves operating and managing hospitals with a focus on delivering quality patient care through a combination of inpatient, outpatient, and emergency services. The company generates revenue through patient billings for medical consultations, diagnostic tests, surgical procedures, room charges, and pharmacy sales.

Revenue Mix

Jupiter Life Line Hospitals operates through its chain of multi-specialty hospitals. While specific numerical breakdowns are not consistently disclosed for all service lines, the company's revenue primarily stems from:

Inpatient Services: This constitutes the majority of revenue, derived from patient admissions for surgeries, complex medical treatments, and long-term care across various specialties.

Outpatient Services: Revenue from consultations, diagnostic imaging, pathology tests, and minor procedures performed in outpatient departments.

Emergency & Critical Care: Services provided in emergency rooms and intensive care units.

Pharmacy & Other Ancillary Services: Income from in-house pharmacies and other support services.

Its hospitals in Thane, Pune, and Indore cater to a broad range of specialties, with strong contributions from areas like cardiac sciences, neurosciences, and orthopedics.

Industry

The Indian hospital and healthcare services industry is characterized by strong growth, driven by increasing disposable incomes, rising health awareness, higher penetration of health insurance, and a growing burden of lifestyle diseases. It is a mix of public and private players, with private corporate hospital chains like Jupiter playing a significant role in tertiary and quaternary care. Jupiter Life Line Hospitals is positioned as a regional leader in Western India, particularly in its primary markets of Thane and Pune, offering high-end multi-specialty care. It competes with other established large corporate hospital chains (e.g., Apollo, Fortis, Max Healthcare in certain geographies) and smaller regional hospital groups, differentiating itself through its strong clinical teams, infrastructure, and patient outcomes in its target areas.

MOAT

Jupiter Life Line Hospitals possesses several competitive advantages:

Regional Brand & Reputation: Established brand name and strong clinical reputation in its key operational geographies (Thane, Pune, Indore), leading to patient trust and preference.

Specialized Infrastructure & Clinical Talent: Investment in advanced medical technology and a strong roster of experienced medical professionals and specialists, enabling it to handle complex tertiary and quaternary cases.

Location Advantage: Strategic locations of its hospitals in densely populated and growing urban centers, ensuring high patient footfall and accessibility.

Operational Efficiency: Demonstrated ability to achieve high bed occupancy rates and manage operations effectively within its existing facilities.

Growth Drivers

Key factors that can drive growth for Jupiter Life Line Hospitals over the next 3-5 years include:

Expansion of Network: Commissioning of new hospitals (e.g., Palghar) and potential bed capacity expansion in existing facilities.

Increasing Healthcare Expenditure: Continued rise in private healthcare spending and health insurance penetration in India.

Medical Tourism: Potential to attract patients from neighboring regions and internationally due to quality healthcare at competitive costs.

Demographic Shifts: Aging population and increasing prevalence of lifestyle diseases driving demand for specialized medical services.

Focus on High-Yield Specialties: Continued emphasis on complex procedures and critical care, which typically command higher revenue per patient.

Risks

Intense Competition: The Indian healthcare market is competitive, with established national chains and new entrants vying for market share, potentially leading to pricing pressures.

Regulatory Changes: Government interventions such as price capping on medical procedures or devices, changes in insurance reimbursement policies, or new licensing requirements could impact profitability.

Talent Retention: Dependence on highly skilled doctors, nurses, and medical staff. Attrition of key personnel could affect service quality and reputation.

High Capital Expenditure: Hospital expansion and technology upgrades require substantial capital investment, posing financial risks if not managed efficiently or if occupancy rates fall short.

Medical Malpractice & Litigation: Risks associated with medical errors or adverse patient outcomes can lead to legal liabilities and reputational damage.

Management & Ownership

The company is promoted by Dr. Ajay Sharma, who also serves as the Managing Director and is a key figure in its clinical and strategic direction. He has significant experience in the healthcare sector. The management team comprises experienced professionals in clinical operations, finance, and administration. The promoter group holds a significant stake in the company, aligning their interests with long-term growth. Post-IPO, there is a mix of promoter holding, institutional investors, and public shareholders, with institutional backing providing governance oversight.

Outlook

Jupiter Life Line Hospitals is well-positioned within the growing Indian healthcare market, benefiting from increasing demand for multi-specialty care and its strong regional presence. Its strategic expansion plans and focus on high-acuity services present avenues for sustained revenue and profit growth. However, the company operates in a capital-intensive and highly regulated industry. Key challenges include managing intense competition, navigating potential regulatory changes that could impact pricing, and effectively attracting and retaining top medical talent. Its ability to successfully execute expansion projects while maintaining operational efficiencies and quality patient outcomes will be crucial for its future performance.

Jupiter Life Line Share Price

Live · BSE / NSE · Inception: 2002
| |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Jupiter Life Line Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 273 291 289 335 333 337 348 394 365 388
Other Income 8 8 7 7 7 7 13 11 9 9
Total Income 281 299 295 342 340 344 360 405 374 397
Total Expenditure 211 228 223 257 256 257 270 301 282 299
Operating Profit 70 71 72 86 84 87 91 104 93 98
Interest 1 1 1 1 3 6 8 8 8 9
Depreciation 11 10 11 14 14 18 21 21 22 23
Exceptional Income / Expenses -0 2 0 0 0 0 0 0 -6 2
Profit Before Tax 58 62 60 70 67 63 62 74 57 68
Provision for Tax 14 17 16 18 15 18 18 17 14 17
Profit After Tax 44 45 45 52 52 45 44 57 42 50
Adjustments 0 -0 -0 -0 -0 -0 -0 -0 0 -0
Profit After Adjustments 44 45 44 52 52 45 44 57 43 50
Adjusted Earnings Per Share 6.7 6.9 6.8 7.9 7.9 6.9 6.7 8.7 6.5 7.7

Jupiter Life Line Profit & Loss

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 463 486 733 893 1073 1262 1495
Other Income 2 4 4 10 22 29 42
Total Income 465 490 737 903 1095 1290 1536
Total Expenditure 380 419 580 691 831 965 1152
Operating Profit 84 71 157 212 264 325 386
Interest 26 39 44 42 26 11 33
Depreciation 26 31 36 39 42 57 87
Exceptional Income / Expenses 0 0 -0 -2 0 0 -4
Profit Before Tax 33 2 77 129 195 258 261
Provision for Tax 3 4 26 56 19 64 66
Profit After Tax 30 -2 51 73 177 194 193
Adjustments 0 0 0 0 1 -1 0
Profit After Adjustments 30 -2 51 73 178 192 194
Adjusted Earnings Per Share 5.8 -0.5 10.1 12.9 27.1 29.3 29.6

Jupiter Life Line Balance Sheet

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 237 239 294 366 1169 1356
Minority's Interest 0 7 -5 -2 -0 0
Borrowings 244 421 465 453 0 322
Other Non-Current Liabilities 20 25 33 37 7 74
Total Current Liabilities 103 96 123 132 106 152
Total Liabilities 603 789 909 986 1281 1905
Fixed Assets 435 630 684 720 718 977
Other Non-Current Assets 35 46 44 57 154 240
Total Current Assets 134 113 180 209 410 687
Total Assets 603 789 909 986 1281 1905

Jupiter Life Line Cash Flow

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 8 7 18 103 26 23
Cash Flow from Operating Activities 74 123 137 117 115 253
Cash Flow from Investing Activities -43 -296 -85 -104 -246 -209
Cash Flow from Financing Activities -32 185 33 18 128 301
Net Cash Inflow / Outflow -1 12 85 31 -3 345
Closing Cash & Cash Equivalent 7 19 103 134 23 368

Jupiter Life Line Ratios

# Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 5.83 -0.45 10.05 12.9 27.13 29.33
CEPS(Rs) 10.92 5.59 17.16 19.72 33.4 38.2
DPS(Rs) 0 0 1 1 1 1
Book NAV/Share(Rs) 46.54 46.98 57.36 64.7 178.3 206.85
Core EBITDA Margin(%) 17.84 13.81 20.92 22.56 22.55 23.51
EBIT Margin(%) 12.65 8.34 16.51 19.16 20.66 21.26
Pre Tax Margin(%) 7.1 0.32 10.52 14.42 18.2 20.43
PAT Margin (%) 6.4 -0.47 6.97 8.17 16.45 15.34
Cash Profit Margin (%) 12 5.85 11.91 12.49 20.4 19.86
ROA(%) 4.91 -0.33 6.02 7.7 15.58 12.15
ROE(%) 12.52 -0.97 19.27 22.18 23.02 15.33
ROCE(%) 11.52 6.91 16.66 21.07 22.14 18.82
Receivable days 35.17 24.95 12.37 15.04 17.49 14.34
Inventory Days 11.01 10.14 7.07 7.02 6.86 6.57
Payable days 267.8 217.2 153.57 153.08 128.08 130.95
PER(x) 0 0 0 0 44.16 54.32
Price/Book(x) 0 0 0 0 6.72 7.7
Dividend Yield(%) 0 0 0 0 0.08 0.06
EV/Net Sales(x) 0.68 0.94 0.6 0.44 7.04 8.15
EV/Core EBITDA(x) 3.74 6.41 2.81 1.85 28.59 31.62
Net Sales Growth(%) 0 5.02 50.8 21.75 20.27 17.52
EBIT Growth(%) 0 -30.81 198.67 41.24 29.7 20.97
PAT Growth(%) 0 -107.75 2325.86 42.59 142.25 9.56
EPS Growth(%) 0 -107.75 2325.71 28.34 110.29 8.14
Debt/Equity(x) 1.15 1.78 1.7 1.28 0 0.24
Current Ratio(x) 1.3 1.18 1.46 1.58 3.87 4.51
Quick Ratio(x) 1.16 1.04 1.34 1.44 3.67 4.35
Interest Cover(x) 2.28 1.04 2.76 4.04 8.42 25.42
Total Debt/Mcap(x) 0 0 0 0 0 0.03

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +18% +20% +22%
Operating Profit CAGR +23% +27% +31%
PAT CAGR +10% +56% +45%
Share Price CAGR -10%
ROE Average +15% +20% +16% +15%
ROCE Average +19% +21% +17% +16%

Jupiter Life Line Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 40.91 %
FII 8.48 %
DII (MF + Insurance) 13.6 %
Public (retail) 59.09 %
# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 40.9140.9140.9140.9140.9140.9140.9140.9140.9140.91
FII 3.974.176.068.8410.0410.039.779.068.488.48
DII 13.9314.1613.8513.4612.3312.2212.4113.5414.0213.6
Public 59.0959.0959.0959.0959.0959.0959.0959.0959.0959.09
Others 0000000000
Total 100100100100100100100100100100

Jupiter Life Line Peer Comparison

Hospital & Healthcare Services Edit Columns

Jupiter Life Line Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Jupiter Life Line Pros & Cons

Pros

  • Company has delivered good profit growth of 45% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 20%
  • Company is almost debt free.

Cons

  • Promoter holding is low: 40.91%.
  • Debtor days have increased from 128.08 to 130.95days.
  • Stock is trading at 5.7 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp